Bradley L. Pentelute

Bradley L. Pentelute
Born (1977-12-05) December 5, 1977
EducationUniversity of Southern California (USC) (B.A., Psychology, B.S., Chemistry)

University of Chicago (M.S., Chemistry, Ph.D., Organic Chemistry)

Harvard Medical School (Fellowship)
OccupationProfessor of Chemistry at Massachusetts Institute of Technology(MIT)
Known forAutomated flow peptide synthesis

Pi-clamp bioconjugation mechanism

Anthrax toxin delivery system

Xenoprotein engineering

Affinity selection-mass spectrometry
AwardsCollier Award

Damon Runyon-Rachleff Innovation Award

Sontag Distinguished Scientist Award

NSF CAREER Award

Sloan Research Fellowship

Amgen Young Investigator Award

Eli Lilly Award
Websitehttp://www.pentelutelabmit.com/

Bradley Lether Pentelute (born December 5, 1977) is currently a professor of chemistry at the Massachusetts Institute of Technology (MIT). His research program lies at the intersection of chemistry and biology and develops bioconjugation strategies, cytosolic delivery platforms, and rapid flow synthesis technologies to optimize the production, achieve site-specific modification, enhance stability, and modulate function of a variety of bioactive agents. His laboratory successfully modified proteins via cysteine-containing “pi-clamps” made up of a short sequence of amino acids, and delivered large biomolecules, such as various proteins and drugs, into cells via the anthrax delivery vehicle. Pentelute has also made several key contributions to automated synthesis technologies in flow. These advances includes the invention of the world's fastest polypeptide synthesizer. This system is able to form amide bonds at a more efficient rate than standard commercial equipment and has helped in the process of understanding protein folding and its mechanisms. This automated flow technology was recently used to achieve total chemical synthesis of protein chains up to 164 amino acids in length that retained the structure and function of native variants obtained by recombinant expression. The primary goal of his endeavor is to use these processes to create designer biologics that can be used to treat diseases and solve the manufacturing problem for on-demand personalized therapies, such as cancer vaccines.